Document Detail

MedLine Citation:
PMID:  15702624     Owner:  NLM     Status:  MEDLINE    
The capacity of microalbuminuria to predict an increased cardiovascular and renal risk is well established in diabetic patients, as well as in essential hypertensive patients and in general population. Detection of microalbuminuria could then be relevant to select specific therapeutic strategies for reducing or preventing cardiovascular events in patients with essential hypertension. Microalbuminuria is detectable in almost 40% of the population with established hypertension, particularly in those patients not controlled satisfactorily with medical therapy. Albuminuria may represent a marker of renal damage and cardiovascular risk in essential hypertension. Microalbuminuria seems to represent a simple and reproducible method to better define cardiovascular risk profile in the hypertensive patient and to stratify the prognosis in relation to renal and cardiovascular risk. ACE-inhibitors and more recently angiotensin II receptor antagonists seem to exhibit a more market capacity to reduce microalbuminuria in patients with essential hypertension or diabetes mellitus. Determination of this parameter in daily clinical practice could facilitate the stratification of risk as well as the choice of therapy in essential hypertensive patients.
J Segura; L M Ruilope; J L Rodicio
Related Documents :
14620924 - Current status of lipid management of hypertensive patients.
15848684 - Comparison between nifedipine and carvedilol in the treatment of de novo arterial hyper...
8872824 - Acceptance and side effects of ambulatory blood pressure monitoring: evaluation of a ne...
16109314 - Serum interleukin-15 concentration in patients with essential hypertension.
16550374 - Takotsubo cardiomyopathy (acute left ventricular apical ballooning syndrome) occurring ...
299664 - Cervical myelography by lateral cervical and lumbar injection of metrizamide. a compari...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  26     ISSN:  1064-1963     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:    2004 Oct-Nov
Date Detail:
Created Date:  2005-02-10     Completed Date:  2005-04-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  701-7     Citation Subset:  IM    
Nephrology Department, Hospital 12 de Octubre, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / epidemiology*
Antihypertensive Agents / therapeutic use
Diabetic Nephropathies / epidemiology*
Hypertension, Renal / drug therapy,  epidemiology*
Risk Factors
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arterial stiffness: pathophysiology and clinical impact.
Next Document:  Comparison of various blood pressure lowering treatments on the primary prevention of cardiovascular...